pharma · Systemic Sclerosis · Nonalcoholic Steatohepatitis · CMMB
Chemomab Therapeutics
Chemomab Therapeutics patent portfolio — 4 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- Tel Aviv, USA
- Founded
- 2011
- Employees
- 20
- Programs
- 6
- Drugs
- 4
- Patents
- 4
Chemomab Therapeutics patents
4 pharmaceutical patents indexed for Chemomab Therapeutics. 0 expire within 24 months.
Chemomab Therapeutics has 4 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12018074
Anti CCL24 (eotaxin2) antibodies for use in the treatment of hepatic diseases
granted -
US 11365246
Anti CCL24 (EOTAXIN2) antibodies for use in the treatment of hepatic diseases
granted -
US 10479830
Anti eotaxin-2 antibodies that recognize additional CCR3-binding chemokines
granted -
US 10246508
Anti eotaxin-2 antibodies that recognize additional CCR3-binding chemokines
granted
Frequently asked questions
How many patents does Chemomab Therapeutics have?
4 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Chemomab Therapeutics patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.